Kipps, T. J., Eradat, H., Grosicki, S., Catalano, J., Cosolo, W., Dyagil, I. S., . . . Pylypenko, H. (2015). A phase 2 study of the BH3 mimetic BCL2 inhibitor navitoclax (ABT-263) with or without rituximab, in previously untreated B-cell chronic lymphocytic leukemia. Leuk Lymphoma.
Dyfyniad Arddull ChicagoKipps, Thomas J., et al. "A Phase 2 Study of the BH3 Mimetic BCL2 Inhibitor Navitoclax (ABT-263) With or Without Rituximab, in Previously Untreated B-cell Chronic Lymphocytic Leukemia." Leuk Lymphoma 2015.
Dyfyniad MLAKipps, Thomas J., et al. "A Phase 2 Study of the BH3 Mimetic BCL2 Inhibitor Navitoclax (ABT-263) With or Without Rituximab, in Previously Untreated B-cell Chronic Lymphocytic Leukemia." Leuk Lymphoma 2015.
Rhybudd: Mae'n bosib nad yw'r dyfyniadau hyn bob amser yn 100% cywir.